Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after tumor progression due to MET polysomy during...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Subjects:	ROS1 MET polysomy Entrectinib Crizotinib Non–small cell lung cancer Case report
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364323000620